Trial Profile
Pilot Project Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2016
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 May 2016 Status changed from recruiting to withdrawn prior to enrolment due to technical difficulties.
- 17 Oct 2014 New trial record